Oryzon Genomics SA
F:ORN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
F:ORN
|
ES |
|
S
|
Schweizer Electronic AG
SWB:SCE
|
DE |
|
Sancus Lending Group Ltd
LSE:LEND
|
GG |
|
I
|
Imperial Brands PLC
XBER:ITB
|
UK |
|
Chengxin Lithium Group Co Ltd
SZSE:002240
|
CN |
|
C
|
Clorox Co
F:CXX
|
US |
|
Amper SA
MAD:AMP
|
ES |
|
M
|
Manulife Financial Corp
XBER:MLU
|
CA |
|
N
|
Network-1 Technologies Inc
AMEX:NTIP
|
US |
|
L
|
Las Vegas Sands Corp
XMUN:LCR
|
US |
|
C
|
Chevron Corp
DUS:CHV
|
US |
|
R
|
Rubellite Energy Inc
TSX:RBY
|
CA |
|
American Water Works Company Inc
NYSE:AWK
|
US |
|
Orion Oyj
F:OFK0
|
FI |
|
Persol Holdings Co Ltd
OTC:TEMPF
|
JP |
|
Verint Systems Inc
F:VTY
|
US |
|
M
|
Mogo Inc
NASDAQ:ORIO
|
CA |
|
W
|
Westlake Corp
F:UEO
|
US |
|
A
|
ALK-Abello A/S
LSE:0OIR
|
DK |
Bankruptcy Probability
Oryzon Genomics SA's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Oryzon Genomics SA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ES |
|
Oryzon Genomics SA
MAD:ORY
|
215.8m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Oryzon Genomics SA's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Oryzon Genomics SA has total debt of 3.1m EUR. This includes both short-term (0 EUR) and long-term (3.1m EUR) debt.
You can find a full breakdown on its Balance Sheet.
